227 related articles for article (PubMed ID: 30685352)
1. Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.
Navarro-Romero A; Vázquez-Oliver A; Gomis-González M; Garzón-Montesinos C; Falcón-Moya R; Pastor A; Martín-García E; Pizarro N; Busquets-Garcia A; Revest JM; Piazza PV; Bosch F; Dierssen M; de la Torre R; Rodríguez-Moreno A; Maldonado R; Ozaita A
Neurobiol Dis; 2019 May; 125():92-106. PubMed ID: 30685352
[TBL] [Abstract][Full Text] [Related]
2. Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits.
Subbanna S; Shivakumar M; Psychoyos D; Xie S; Basavarajappa BS
J Neurosci; 2013 Apr; 33(15):6350-66. PubMed ID: 23575834
[TBL] [Abstract][Full Text] [Related]
3. CB
Saravia R; Flores Á; Plaza-Zabala A; Busquets-Garcia A; Pastor A; de la Torre R; Di Marzo V; Marsicano G; Ozaita A; Maldonado R; Berrendero F
Biol Psychiatry; 2017 Apr; 81(7):625-634. PubMed ID: 27737762
[TBL] [Abstract][Full Text] [Related]
4. Acute Ethanol Inhibition of Adult Hippocampal Neurogenesis Involves CB1 Cannabinoid Receptor Signaling.
Khatri D; Laroche G; Grant ML; Jones VM; Vetreno RP; Crews FT; Mukhopadhyay S
Alcohol Clin Exp Res; 2018 Apr; 42(4):718-726. PubMed ID: 29417597
[TBL] [Abstract][Full Text] [Related]
5. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
Bianchi P; Ciani E; Guidi S; Trazzi S; Felice D; Grossi G; Fernandez M; Giuliani A; Calzà L; Bartesaghi R
J Neurosci; 2010 Jun; 30(26):8769-79. PubMed ID: 20592198
[TBL] [Abstract][Full Text] [Related]
6. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
8. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J
Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
[TBL] [Abstract][Full Text] [Related]
12. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
[TBL] [Abstract][Full Text] [Related]
13. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
Lipina C; Vaanholt LM; Davidova A; Mitchell SE; Storey-Gordon E; Hambly C; Irving AJ; Speakman JR; Hundal HS
Aging Cell; 2016 Apr; 15(2):325-35. PubMed ID: 26757949
[TBL] [Abstract][Full Text] [Related]
14. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome.
Navarro-Romero A; Galera-López L; Ortiz-Romero P; Llorente-Ovejero A; de Los Reyes-Ramírez L; Bengoetxea de Tena I; Garcia-Elias A; Mas-Stachurska A; Reixachs-Solé M; Pastor A; de la Torre R; Maldonado R; Benito B; Eyras E; Rodríguez-Puertas R; Campuzano V; Ozaita A
Elife; 2022 Oct; 11():. PubMed ID: 36217821
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of the neuronal CB1 cannabinoid receptor in the hippocampus of male Ts65Dn Down syndrome mouse model.
Di Franco N; Drutel G; Roullot-Lacarrière V; Julio-Kalajzic F; Lalanne V; Grel A; Leste-Lasserre T; Matias I; Cannich A; Gonzales D; Simon V; Cota D; Marsicano G; Piazza PV; Vallée M; Revest JM
Mol Cell Neurosci; 2022 Mar; 119():103705. PubMed ID: 35158060
[TBL] [Abstract][Full Text] [Related]
17. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.
Parrini M; Ghezzi D; Deidda G; Medrihan L; Castroflorio E; Alberti M; Baldelli P; Cancedda L; Contestabile A
Sci Rep; 2017 Dec; 7(1):16825. PubMed ID: 29203796
[TBL] [Abstract][Full Text] [Related]
18. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.
Velazquez R; Ash JA; Powers BE; Kelley CM; Strawderman M; Luscher ZI; Ginsberg SD; Mufson EJ; Strupp BJ
Neurobiol Dis; 2013 Oct; 58():92-101. PubMed ID: 23643842
[TBL] [Abstract][Full Text] [Related]
19. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R
Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313
[TBL] [Abstract][Full Text] [Related]
20. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
